title: Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma.
abstract: OBJECTIVE
  To evaluate the intraocular pressure (IOP)-lowering potential of anecortave acetate (AA) in eyes with steroid-related ocular hypertension inadequately controlled with the maximal tolerated or appropriate medical therapy.
  
  
  METHODS
  Uncontrolled case series.
  
  
  METHODS
  A total of 8 eyes of 7 subjects with medically uncontrolled IOP following intravitreal or sub-Tenon injections of triamcinolone acetonide were included. All received an 0.8-mL anterior juxtascleral depot of 3% AA solution (24 mg) under topical anesthesia. The IOP was assessed weekly for the first month, then monthly for a minimum of 1 year.
  
  
  RESULTS
  The mean baseline IOP was 39.9 mm Hg. After 1 week, the mean IOP decreased 12 mm Hg (29%; P = .005) and by 1 month, the mean IOP had decreased 14.1 mm Hg (34.5%; P = .003) from baseline. Four eyes required surgical intervention despite a decrease in IOP because of markedly elevated initial IOP and the degree of preexisting glaucomatous optic neuropathy. We observed no adverse events.
  
  
  CONCLUSIONS
  An anterior juxtascleral depot of AA lowers IOP substantially in some eyes with medically uncontrolled steroid-related ocular hypertension. Further study is warranted to clarify the role of AA in treating this condition as well as other forms of glaucoma.
authors.affiliation: Bloomberg School of Public Health and Wilmer Institute, Johns Hopkins University, Baltimore, Maryland, USA. arobin@glaucomaexpert.com
authors.forename: Alan L
authors.initials: AL
authors.lastname: Robin
authors.forename: Eric P
authors.initials: EP
authors.lastname: Suan
authors.forename: Raymond N
authors.initials: RN
authors.lastname: Sjaarda
authors.forename: David G
authors.initials: DG
authors.lastname: Callanan
authors.forename: Joseph
authors.initials: J
authors.lastname: Defaller
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced / Q000188:drug therapy*; D011244:Pregnadienediols / Q000627:therapeutic use*; D011446:Prospective Studies; D012164:Retinal Diseases / Q000188:drug therapy; D014065:Tonometry, Ocular; D014222:Triamcinolone Acetonide / Q000009:adverse effects*; D014822:Vitreous Body
chemical_list: D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D005938:Glucocorticoids; D011244:Pregnadienediols; D014222:Triamcinolone Acetonide; C418047:anecortave acetate